2003 Clinical Development Licensing Treatment 
The Pharma Data
APRIL 14, 2021
Xolair for self-injection offers healthcare providers and appr opriate patients another administration option for more flexibility in managing their treatment. Roche’s Chief Medical Officer and Head of Global Product Development. with Xolair since its initial approval in 2003. today announced that the U.S. indications.
The Pharma Data
MARCH 8, 2021
“We are very pleased to share our initial Phase 2 infectivity data at this important conference, which remains at the forefront for critical clinical scientific information in infectious diseases,” shared Dr. Wendy Painter, Chief Medical Officer of Ridgeback Biotherapeutics. “At About Molnupiravir.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
OCTOBER 16, 2023
Indeed, this is bolstered by top tier universities like Newcastle University, which specialises in structure-based approaches for drug discovery, developing innovative technologies that support the identification of new medicines, and is well-established in cancer drug discovery.
The Pharma Data
NOVEMBER 5, 2020
has been appointed to the additional role of president and will oversee the growth of the company’s technology portfolio for the treatment of ischemic and hemorrhagic stroke. Taveras will lead all research and non-clinical development functions supporting the company’s pipeline of investigational therapies. from 1993 to 1995.
The Pharma Data
FEBRUARY 25, 2021
Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac , its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older. 5 Currently there is no cure or treatment for TBE, only management of symptoms.
Expert insights. Personalized for you.
52 
Let's personalize your content